Identification

Name
Phentermine
Accession Number
DB00191  (APRD00093)
Type
Small Molecule
Groups
Approved, Illicit
Description

A central nervous system stimulant and sympathomimetic with actions and uses similar to those of dextroamphetamine. It has been used most frequently in the treatment of obesity. [PubChem]. Some common brand names for phentermine are Adipex-P® and Suprenza™. Phentermine is also available in combination medications such as Qsymia®.

Structure
Thumb
Synonyms
  • alpha,alpha-Dimethylphenethylamine
  • Fentermina
  • Phentermine resin
  • Phenterminum
Product Ingredients
IngredientUNIICASInChI Key
Phentermine Hydrochloride0K2I505OTV1197-21-3NCAIGTHBQTXTLR-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fastin Cap 30mgCapsule30 mgOralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1993-12-311999-02-02Canada
IonaminCapsule15 mgOralSanofi Aventis1958-12-312007-10-17Canada
IonaminCapsule30 mgOralSanofi Aventis1958-12-312007-10-17Canada
SuprenzaTablet, orally disintegrating15 mg/1OralAkrimax Pharmaceuticals, LLC2012-12-14Not applicableUs
SuprenzaTablet, orally disintegrating30 mg/1OralAkrimax Pharmaceuticals, LLC2012-12-14Not applicableUs
SuprenzaTablet, orally disintegrating37.5 mg/1OralAkrimax Pharmaceuticals, LLC2012-12-14Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Adipex-PTablet37.5 mg/1OralA S Medication Solutions1990-09-302017-06-20Us
Adipex-PTablet37.5 mg/1OralTeva Select Brands1990-09-30Not applicableUs
Adipex-PTablet37.5 mg/1OralA S Medication Solutions1990-09-302017-06-20Us57844 0009 01 nlmimage10 95354aba
Adipex-PCapsule37.5 mg/1OralTeva Select Brands1990-09-30Not applicableUs57844 0019 01 nlmimage10 8445420a
Adipex-PTablet37.5 mg/1OralPd Rx Pharmaceuticals, Inc.1990-09-30Not applicableUs
LomairaTablet8 mg/1OralKvk Tech,Inc2016-09-12Not applicableUs
PhentermineCapsule30 mg/1OralAurolife Pharma, LLC2016-11-11Not applicableUs
PhentermineCapsule15 mg/1OralAurolife Pharma, LLC2016-11-11Not applicableUs
Phentermine HClCapsule15 mg/1OralNorthwind Pharmaceuticals2017-08-22Not applicableUs
Phentermine HClCapsule30 mg/1OralDirectrx2016-07-11Not applicableUs
International/Other Brands
Duromine / Fastin / Ionamin / Obenix / Obestin-30 / Phentercot / Phentride / Pro-Fast / Teramine / Zantryl
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
QsymiaPhentermine Hydrochloride (3.75 mg/1) + Topiramate (23 mg/1)Capsule, extended releaseOralVIVUS, Inc.2012-09-17Not applicableUs
QsymiaPhentermine Hydrochloride (15 mg/1) + Topiramate (92 mg/1)Capsule, extended releaseOralVIVUS, Inc.2012-09-17Not applicableUs
QsymiaPhentermine Hydrochloride (7.5 mg/1) + Topiramate (46 mg/1)Capsule, extended releaseOralVIVUS, Inc.2012-09-17Not applicableUs
QsymiaPhentermine Hydrochloride (11.25 mg/1) + Topiramate (69 mg/1)Capsule, extended releaseOralVIVUS, Inc.2012-09-17Not applicableUs
Categories
UNII
C045TQL4WP
CAS number
122-09-8
Weight
Average: 149.2328
Monoisotopic: 149.120449485
Chemical Formula
C10H15N
InChI Key
DHHVAGZRUROJKS-UHFFFAOYSA-N
InChI
InChI=1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3
IUPAC Name
2-methyl-1-phenylpropan-2-amine
SMILES
CC(C)(N)CC1=CC=CC=C1

Pharmacology

Indication

For the treatment and management of obesity.

Structured Indications
Pharmacodynamics

Phentermine is indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction. Phentermine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.

Mechanism of action

Phentermine is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. The drug seems to inhibit reuptake of noradrenaline, dopamine, and seratonin through inhibition or reversal of the reuptake transporters. It may also inhibit MAO enzymes leaving more neurotransmitter available at the synapse.Phentermine (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that phentermine can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage.

TargetActionsOrganism
ASodium-dependent noradrenaline transporter
inhibitor
Human
ASodium-dependent serotonin transporter
inhibitor
Human
ASodium-dependent dopamine transporter
inhibitor
Human
AAmine oxidase [flavin-containing] A
antagonist
Human
AAmine oxidase [flavin-containing] B
antagonist
Human
Absorption

Phentermine is rapidly absorbed after oral ingestion.

Volume of distribution
Not Available
Protein binding

Approximately 96.3%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

16 to 31 hours

Clearance
Not Available
Toxicity

LD50 is adult monkeys is 15 to 20 mg/kg. Symptoms of overdose include delirium, mania, self-injury, marked hypertension, tachycardia, arrhythmia, hyperpyrexia, convulsion, coma, and circulatory collapse.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Phentermine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Phentermine is combined with Acebutolol.Approved
AcepromazineAcepromazine may decrease the stimulatory activities of Phentermine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Phentermine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Phentermine.Approved
AcrivastinePhentermine may decrease the sedative activities of Acrivastine.Approved
AlcaftadinePhentermine may decrease the sedative activities of Alcaftadine.Approved
AlfentanilPhentermine may increase the analgesic activities of Alfentanil.Approved, Illicit
AlgeldrateAlgeldrate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Experimental
AlimemazinePhentermine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlmagateAlmagate may decrease the excretion rate of Phentermine which could result in a higher serum level.Experimental
AlmasilateAlmasilate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Experimental
AloglutamolAloglutamol may decrease the excretion rate of Phentermine which could result in a higher serum level.Experimental
AlphacetylmethadolPhentermine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodinePhentermine may increase the analgesic activities of Alphaprodine.Illicit
AluminiumAluminium may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of Phentermine which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of Phentermine which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
AmineptineAmineptine may increase the stimulatory activities of Phentermine.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of Phentermine.Approved, Investigational
AmitriptylineAmitriptyline may increase the stimulatory activities of Phentermine.Approved
Ammonium chlorideThe serum concentration of Phentermine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmperozideAmperozide may decrease the stimulatory activities of Phentermine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Phentermine.Approved, Illicit
AntazolinePhentermine may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of Phentermine.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of Phentermine.Approved
AstemizolePhentermine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AtomoxetineAtomoxetine may increase the hypertensive activities of Phentermine.Approved
AzaperoneAzaperone may decrease the stimulatory activities of Phentermine.Investigational, Vet Approved
AzatadinePhentermine may decrease the sedative activities of Azatadine.Approved
AzelastinePhentermine may decrease the sedative activities of Azelastine.Approved
BamipinePhentermine may decrease the sedative activities of Bamipine.Experimental
BenmoxinBenmoxin may increase the hypertensive activities of Phentermine.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Phentermine.Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Phentermine is combined with Benzphetamine.Approved, Illicit
BezitramidePhentermine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Phentermine.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of Phentermine which could result in a higher serum level.Experimental
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Phentermine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Phentermine is combined with Brofaromine.Experimental
BromperidolBromperidol may decrease the stimulatory activities of Phentermine.Investigational
BrompheniraminePhentermine may decrease the sedative activities of Brompheniramine.Approved
BucindololThe risk or severity of adverse effects can be increased when Phentermine is combined with Bucindolol.Investigational
BuclizinePhentermine may decrease the sedative activities of Buclizine.Approved
BuprenorphinePhentermine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButaperazineButaperazine may decrease the stimulatory activities of Phentermine.Experimental
ButorphanolPhentermine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Butyric AcidPhentermine may decrease the sedative activities of Butyric Acid.Experimental, Investigational
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
Calcium silicateCalcium silicate may decrease the excretion rate of Phentermine which could result in a higher serum level.Experimental
CarbinoxaminePhentermine may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilPhentermine may increase the analgesic activities of Carfentanil.Illicit, Investigational, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Phentermine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Phentermine.Withdrawn
CeliprololThe risk or severity of adverse effects can be increased when Phentermine is combined with Celiprolol.Approved, Investigational
CetirizinePhentermine may decrease the sedative activities of Cetirizine.Approved
ChloropyraminePhentermine may decrease the sedative activities of Chloropyramine.Approved
ChlorphenaminePhentermine may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxaminePhentermine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorphentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Chlorphentermine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of Phentermine.Experimental
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Phentermine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Phentermine.Approved, Investigational, Withdrawn
CimetidinePhentermine may decrease the sedative activities of Cimetidine.Approved
CinnarizinePhentermine may decrease the sedative activities of Cinnarizine.Approved, Investigational
ClemastinePhentermine may decrease the sedative activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Phentermine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineClomipramine may increase the stimulatory activities of Phentermine.Approved, Vet Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of Phentermine.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of Phentermine.Experimental
ClozapineClozapine may decrease the stimulatory activities of Phentermine.Approved
CodeinePhentermine may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of Phentermine.Approved
CyclizinePhentermine may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of Phentermine.Approved
CyproheptadinePhentermine may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Phentermine.Approved
DesipramineDesipramine may increase the stimulatory activities of Phentermine.Approved
DesloratadinePhentermine may decrease the sedative activities of Desloratadine.Approved, Investigational
DexbrompheniraminePhentermine may decrease the sedative activities of Dexbrompheniramine.Approved
DexchlorpheniraminePhentermine may decrease the sedative activities of Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleatePhentermine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DextromoramidePhentermine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxyphenePhentermine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocinePhentermine may increase the analgesic activities of Dezocine.Approved, Investigational
DibenzepinDibenzepin may increase the stimulatory activities of Phentermine.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
DihydrocodeinePhentermine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroetorphinePhentermine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphinePhentermine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DimenhydrinatePhentermine may decrease the sedative activities of Dimenhydrinate.Approved
DimetindenePhentermine may decrease the sedative activities of Dimetindene.Approved, Investigational
DimetotiazinePhentermine may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydraminePhentermine may decrease the sedative activities of Diphenhydramine.Approved
DiphenoxylatePhentermine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DixyrazineDixyrazine may decrease the stimulatory activities of Phentermine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Phentermine is combined with Dobutamine.Approved
DopamineThe risk or severity of adverse effects can be increased when Phentermine is combined with Dopamine.Approved
DosulepinDosulepin may increase the stimulatory activities of Phentermine.Approved
DoxepinPhentermine may decrease the sedative activities of Doxepin.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Phentermine is combined with Doxofylline.Approved
DoxylaminePhentermine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPEPhentermine may increase the analgesic activities of DPDPE.Investigational
DronabinolDronabinol may increase the tachycardic activities of Phentermine.Approved, Illicit
DroperidolDroperidol may decrease the stimulatory activities of Phentermine.Approved, Vet Approved
EbastinePhentermine may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of Phentermine.Investigational
EmedastinePhentermine may decrease the sedative activities of Emedastine.Approved
EpanololThe risk or severity of adverse effects can be increased when Phentermine is combined with Epanolol.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Ephedrine.Approved
EpinastinePhentermine may decrease the sedative activities of Epinastine.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Epinephrine.Approved, Vet Approved
EsmirtazapinePhentermine may decrease the sedative activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Phentermine.Approved
EthopropazinePhentermine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Phentermine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Phentermine which could result in a higher serum level.Withdrawn
EthylmorphinePhentermine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtilefrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Etilefrine.Withdrawn
EtorphinePhentermine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidinePhentermine may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of Phentermine.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Phentermine is combined with Fenoterol.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Phentermine is combined with Fenozolone.Experimental
FentanylPhentermine may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Phentermine.Approved
FexofenadinePhentermine may decrease the sedative activities of Fexofenadine.Approved
FluanisoneFluanisone may decrease the stimulatory activities of Phentermine.Experimental
FlunarizinePhentermine may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Phentermine.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Phentermine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Phentermine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Phentermine.Approved, Investigational, Vet Approved
Glutamic AcidThe serum concentration of Phentermine can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GuanethidineThe serum concentration of Phentermine can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of Phentermine.Approved
HarmalineThe risk or severity of adverse effects can be increased when Phentermine is combined with Harmaline.Experimental
HeroinPhentermine may increase the analgesic activities of Heroin.Approved, Illicit, Investigational
HydracarbazineHydracarbazine may increase the hypertensive activities of Phentermine.Experimental
HydrocodonePhentermine may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphonePhentermine may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of Phentermine which could result in a higher serum level.Experimental, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Phentermine is combined with Hydroxyamphetamine.Approved
HydroxyzinePhentermine may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Phentermine.Approved
ImipramineImipramine may increase the stimulatory activities of Phentermine.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Phentermine.Approved, Investigational
Ioflupane I-123Phentermine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may increase the stimulatory activities of Phentermine.Experimental
IproclozideIproclozide may increase the hypertensive activities of Phentermine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Phentermine.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Phentermine.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Phentermine is combined with Isoprenaline.Approved
IsothipendylPhentermine may decrease the sedative activities of Isothipendyl.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Phentermine is combined with Isoxsuprine.Approved, Withdrawn
KetobemidonePhentermine may increase the analgesic activities of Ketobemidone.Approved, Investigational
KetotifenPhentermine may decrease the sedative activities of Ketotifen.Approved
LabetalolThe risk or severity of adverse effects can be increased when Phentermine is combined with Labetalol.Approved
LafutidinePhentermine may decrease the sedative activities of Lafutidine.Investigational
LavoltidinePhentermine may decrease the sedative activities of Lavoltidine.Investigational
LevocabastinePhentermine may decrease the sedative activities of Levocabastine.Approved
LevocetirizinePhentermine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetatePhentermine may increase the analgesic activities of Levomethadyl Acetate.Approved, Investigational
LevorphanolPhentermine may increase the analgesic activities of Levorphanol.Approved
LinezolidLinezolid may increase the hypertensive activities of Phentermine.Approved, Investigational
LithiumLithium may decrease the stimulatory activities of Phentermine.Approved
LodoxamidePhentermine may decrease the sedative activities of Lodoxamide.Approved
LofentanilPhentermine may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may increase the stimulatory activities of Phentermine.Experimental
LoratadinePhentermine may decrease the sedative activities of Loratadine.Approved
LoxapineLoxapine may decrease the stimulatory activities of Phentermine.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Phentermine.Approved
MagaldrateMagaldrate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of Phentermine which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of Phentermine.Withdrawn
MeclizinePhentermine may decrease the sedative activities of Meclizine.Approved
MefenorexThe risk or severity of adverse effects can be increased when Phentermine is combined with Mefenorex.Experimental
MelperoneMelperone may decrease the stimulatory activities of Phentermine.Approved, Investigational
MephentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Mephentermine.Approved
MeptazinolPhentermine may increase the analgesic activities of Meptazinol.Experimental
MepyraminePhentermine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazinePhentermine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Phentermine.Approved, Investigational
MetaraminolThe risk or severity of adverse effects can be increased when Phentermine is combined with Metaraminol.Approved, Investigational
MethadonePhentermine may increase the analgesic activities of Methadone.Approved
Methadyl AcetatePhentermine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Phentermine is combined with Methamphetamine.Approved, Illicit
MethapyrilenePhentermine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved
MethenamineThe serum concentration of Phentermine can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Phentermine.Approved
MethoxamineThe risk or severity of adverse effects can be increased when Phentermine is combined with Methoxamine.Approved, Investigational
Methylene blueMethylene blue may increase the hypertensive activities of Phentermine.Approved, Investigational
MetiamidePhentermine may decrease the sedative activities of Metiamide.Experimental
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Phentermine.Approved, Investigational
MianserinPhentermine may decrease the sedative activities of Mianserin.Approved, Investigational
MidodrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Midodrine.Approved
MinaprineMinaprine may increase the hypertensive activities of Phentermine.Approved
MirtazapinePhentermine may decrease the sedative activities of Mirtazapine.Approved
MizolastinePhentermine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Phentermine.Approved
MolindoneMolindone may decrease the stimulatory activities of Phentermine.Approved
MoperoneMoperone may decrease the stimulatory activities of Phentermine.Experimental
MorphinePhentermine may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of Phentermine.Experimental
NabiloneNabilone may increase the tachycardic activities of Phentermine.Approved, Investigational
NalbuphinePhentermine may increase the analgesic activities of Nalbuphine.Approved
NialamideNialamide may increase the hypertensive activities of Phentermine.Withdrawn
NicomorphinePhentermine may increase the analgesic activities of Nicomorphine.Experimental
NizatidinePhentermine may decrease the sedative activities of Nizatidine.Approved
NorepinephrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Norepinephrine.Approved
NormethadonePhentermine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the stimulatory activities of Phentermine.Approved
NylidrinThe risk or severity of adverse effects can be increased when Phentermine is combined with Nylidrin.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Phentermine.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of Phentermine.Approved, Investigational
OlopatadinePhentermine may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of Phentermine.Approved
OpipramolOpipramol may increase the stimulatory activities of Phentermine.Investigational
OpiumPhentermine may increase the analgesic activities of Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Phentermine is combined with Orciprenaline.Approved
OsanetantOsanetant may decrease the stimulatory activities of Phentermine.Investigational
OxatomidePhentermine may decrease the sedative activities of Oxatomide.Investigational
OxycodonePhentermine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymetazolineThe risk or severity of adverse effects can be increased when Phentermine is combined with Oxymetazoline.Approved
OxymorphonePhentermine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of Phentermine.Experimental
OzagrelPhentermine may decrease the sedative activities of Ozagrel.Investigational
PaliperidonePaliperidone may decrease the stimulatory activities of Phentermine.Approved
PargylinePargyline may increase the hypertensive activities of Phentermine.Approved
PemirolastPhentermine may decrease the sedative activities of Pemirolast.Approved, Investigational
PenfluridolPenfluridol may decrease the stimulatory activities of Phentermine.Experimental
PentazocinePhentermine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of Phentermine.Investigational
PerospironePerospirone may decrease the stimulatory activities of Phentermine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Phentermine.Approved
PethidinePhentermine may increase the analgesic activities of Pethidine.Approved
PhenazocinePhentermine may increase the analgesic activities of Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Phentermine.Approved
PhenindaminePhentermine may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Phentermine.Withdrawn
PheniraminePhentermine may decrease the sedative activities of Pheniramine.Approved
PhenmetrazineThe risk or severity of adverse effects can be increased when Phentermine is combined with Phenmetrazine.Approved, Illicit
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Phentermine.Approved
PhenoperidinePhentermine may increase the analgesic activities of Phenoperidine.Experimental
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Phentermine.Withdrawn
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Phentermine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Phentermine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Phentermine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Phentermine.Approved
PipamperonePipamperone may decrease the stimulatory activities of Phentermine.Approved, Investigational
PipotiazinePipotiazine may decrease the stimulatory activities of Phentermine.Approved, Investigational
PiritramidePhentermine may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of Phentermine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Phentermine.Withdrawn
PrenalterolThe risk or severity of adverse effects can be increased when Phentermine is combined with Prenalterol.Experimental
ProcaterolThe risk or severity of adverse effects can be increased when Phentermine is combined with Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Phentermine.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of Phentermine.Approved, Vet Approved
PromethazinePhentermine may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of Phentermine.Approved
ProthipendylProthipendyl may decrease the stimulatory activities of Phentermine.Investigational
ProtriptylineProtriptyline may increase the stimulatory activities of Phentermine.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Pseudoephedrine.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of Phentermine.Approved
QuifenadinePhentermine may decrease the sedative activities of Quifenadine.Experimental
RacepinephrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Racepinephrine.Approved
RacloprideRaclopride may decrease the stimulatory activities of Phentermine.Investigational
RanitidinePhentermine may decrease the sedative activities of Ranitidine.Approved
RasagilineRasagiline may increase the hypertensive activities of Phentermine.Approved
RemifentanilPhentermine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Phentermine.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Phentermine.Approved, Investigational
RisperidoneRisperidone may decrease the stimulatory activities of Phentermine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Phentermine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Ritodrine.Approved, Investigational
Roxatidine acetatePhentermine may decrease the sedative activities of Roxatidine acetate.Approved, Investigational
SafrazineSafrazine may increase the hypertensive activities of Phentermine.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Phentermine is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Phentermine.Approved, Investigational, Withdrawn
SufentanilPhentermine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of Phentermine.Approved, Investigational
SultoprideSultopride may decrease the stimulatory activities of Phentermine.Experimental
SynephrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Synephrine.Experimental
TapentadolPhentermine may increase the analgesic activities of Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Phentermine.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Phentermine is combined with Terbutaline.Approved
TerfenadinePhentermine may decrease the sedative activities of Terfenadine.Withdrawn
TesmilifenePhentermine may decrease the sedative activities of Tesmilifene.Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of Phentermine.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Phentermine is combined with Tetryzoline.Approved
ThiopropazateThiopropazate may decrease the stimulatory activities of Phentermine.Experimental
ThioproperazineThioproperazine may decrease the stimulatory activities of Phentermine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Phentermine.Approved, Withdrawn
ThiothixeneThiothixene may decrease the stimulatory activities of Phentermine.Approved
ThonzylaminePhentermine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of Phentermine.Approved, Investigational
TiaprideTiapride may decrease the stimulatory activities of Phentermine.Approved, Investigational
TilidinePhentermine may increase the analgesic activities of Tilidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Phentermine.Approved
TramadolPhentermine may increase the analgesic activities of Tramadol.Approved, Investigational
TramazolineThe risk or severity of adverse effects can be increased when Phentermine is combined with Tramazoline.Investigational
TranilastPhentermine may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Phentermine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Phentermine.Approved
TretoquinolThe risk or severity of adverse effects can be increased when Phentermine is combined with Tretoquinol.Experimental
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Phentermine.Approved
TrifluperidolTrifluperidol may decrease the stimulatory activities of Phentermine.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of Phentermine.Approved, Vet Approved
TrimipramineTrimipramine may increase the stimulatory activities of Phentermine.Approved
TripelennaminePhentermine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidinePhentermine may decrease the sedative activities of Triprolidine.Approved
TritoqualinePhentermine may decrease the sedative activities of Tritoqualine.Experimental
TyramineThe risk or severity of adverse effects can be increased when Phentermine is combined with Tyramine.Investigational, Nutraceutical
VeraliprideVeralipride may decrease the stimulatory activities of Phentermine.Experimental
Vitamin CThe serum concentration of Phentermine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneZiprasidone may decrease the stimulatory activities of Phentermine.Approved
ZotepineZotepine may decrease the stimulatory activities of Phentermine.Approved, Investigational
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Phentermine.Approved, Investigational
Food Interactions
  • Limit caffeine intake.
  • Take without regard to meals.

References

General References
  1. Bray GA: A concise review on the therapeutics of obesity. Nutrition. 2000 Oct;16(10):953-60. [PubMed:11054601]
  2. Nelson DL, Gehlert DR: Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine. 2006 Feb;29(1):49-60. [PubMed:16622292]
External Links
Human Metabolome Database
HMDB14337
KEGG Drug
D05458
KEGG Compound
C07438
PubChem Compound
4771
PubChem Substance
46508515
ChemSpider
4607
BindingDB
50246598
ChEBI
8080
ChEMBL
CHEMBL1574
Therapeutic Targets Database
DAP000719
PharmGKB
PA164748099
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Phentermine
ATC Codes
A08AA01 — Phentermine
FDA label
Download (159 KB)
MSDS
Download (48.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentBMI >30 kg/m2 / Hypertensive1
1Active Not RecruitingTreatmentBinge Eating Disorder (BED) / Bulimia Nervosa (BN)1
1CompletedNot AvailableDrug Abuse1
1CompletedTreatmentBMI >30 kg/m21
1CompletedTreatmentDrug Abuse / Healthy Volunteers1
1CompletedTreatmentHepatic Impairment1
1CompletedTreatmentImpaired Renal Function1
1RecruitingBasic ScienceCocaine Use Disorders1
1WithdrawnBasic ScienceDrug Abuse / Healthy Volunteers1
2Active Not RecruitingTreatmentBariatric Surgery Procedures / BMI >30 kg/m2 / Metabolic Surgery / Obese experiencing rapid weight loss1
2CompletedTreatmentBMI >27 kg/m2 / BMI >30 kg/m21
2CompletedTreatmentBMI >30 kg/m21
2CompletedTreatmentBMI >30 kg/m2 / Heart Diseases / Vascular Diseases1
2CompletedTreatmentBinge Eating Disorder (BED)1
2CompletedTreatmentDiabetes1
3CompletedTreatmentBMI >30 kg/m22
3RecruitingTreatmentBMI >30 kg/m2 / Polycystic Ovaries Syndrome1
4Active Not RecruitingTreatmentBMI >30 kg/m21
4CompletedTreatmentBMI >30 kg/m22
4Unknown StatusNot AvailableBMI >30 kg/m21
Not AvailableCompletedBasic ScienceBMI >27 kg/m2 / BMI >30 kg/m2 / Metabolic Diseases1
Not AvailableWithdrawnTreatmentBMI >30 kg/m21

Pharmacoeconomics

Manufacturers
  • Baxter healthcare corp anesthesia critical care
  • Teva pharmaceuticals usa inc
  • Glaxosmithkline
  • Ferndale laboratories inc
  • Shire richwood inc
  • Mm mast and co
  • Abc holding corp
  • Able laboratories inc
  • Actavis totowa llc
  • Barr laboratories inc
  • Camall co inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Ivax pharmaceuticals inc
  • Kvk tech inc
  • Lannett co inc
  • Lannett holdings inc
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Tg united inc
  • Tg united labs llc
  • Usl pharma inc
  • Vitarine pharmaceuticals inc
  • Watson laboratories inc
  • Actavis elizabeth llc
  • Caraco pharmaceutical laboratories ltd
  • Vintage pharmaceuticals inc
  • Solvay pharmaceuticals
  • Ucb inc
  • Quantum pharmics ltd
Packagers
Dosage forms
FormRouteStrength
CapsuleOral30 mg
CapsuleOral15 mg
TabletOral8 mg/1
CapsuleOral15 mg/1
CapsuleOral30 mg/1
CapsuleOral37.5 mg/1
TabletOral30 mg/1
TabletOral37.5 mg/1
Capsule, extended releaseOral15 mg/1
Capsule, extended releaseOral30 mg/1
Capsule, extended releaseOral
Tablet, orally disintegratingOral15 mg/1
Tablet, orally disintegratingOral30 mg/1
Tablet, orally disintegratingOral37.5 mg/1
Prices
Unit descriptionCostUnit
Phentermine hcl powder10.71USD g
Ionamin 30 mg capsule sa2.87USD capsule
Adipex-P 37.5 mg capsule2.2USD capsule
Adipex-p 37.5 mg tablet2.15USD tablet
Phentermine 37.5 mg tablet1.54USD tablet
Phentermine HCl 15 mg capsule1.18USD capsule
Phentermine HCl 30 mg capsule1.17USD capsule
Ionamin 15 mg capsule sa1.15USD capsule
Phentermine HCl 37.5 mg capsule1.0USD capsule
Phentermine HCl 37.5 mg tablet1.0USD tablet
Phentermine 8 mg tablet0.54USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6071537No1997-06-232017-06-23Us
US8895057No2008-06-092028-06-09Us
US7056890No2000-06-142020-06-14Us
US7553818No2000-06-142020-06-14Us
US7659256No2000-06-142020-06-14Us
US7674776No2000-06-142020-06-14Us
US8580299No2009-06-142029-06-14Us
US9011906No2008-06-092028-06-09Us
US9011905No2008-06-092028-06-09Us
US8895058No2008-06-092028-06-09Us
US8580298No2009-05-152029-05-15Us
US6149938No1998-07-232018-07-23Us
US8440170No2009-03-142029-03-14Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)205 °CNot Available
water solubility18.6 g/LNot Available
logP1.90HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.757 mg/mLALOGPS
logP2.32ALOGPS
logP2.08ChemAxon
logS-2.3ALOGPS
pKa (Strongest Basic)10.25ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity48.34 m3·mol-1ChemAxon
Polarizability17.87 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier+0.959
Caco-2 permeable+0.7688
P-glycoprotein substrateNon-substrate0.6477
P-glycoprotein inhibitor INon-inhibitor0.934
P-glycoprotein inhibitor IINon-inhibitor0.9801
Renal organic cation transporterNon-inhibitor0.8236
CYP450 2C9 substrateNon-substrate0.8411
CYP450 2D6 substrateSubstrate0.7204
CYP450 3A4 substrateNon-substrate0.6493
CYP450 1A2 substrateNon-inhibitor0.7962
CYP450 2C9 inhibitorNon-inhibitor0.8861
CYP450 2D6 inhibitorInhibitor0.7825
CYP450 2C19 inhibitorNon-inhibitor0.8996
CYP450 3A4 inhibitorNon-inhibitor0.7348
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8782
Ames testNon AMES toxic0.9681
CarcinogenicityNon-carcinogens0.6949
BiodegradationNot ready biodegradable0.9303
Rat acute toxicity2.8400 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9867
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.33 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0a4i-9100000000-7037d3f1fad22de72c33
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ue9-0900000000-f2eb273dfd0ec45869c5
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0f89-2900000000-f527ee48b9e2784c178c
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0159-4900000000-548f73a83354267c9f81
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-0900000000-c7ab0aa268d14ae3da39
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-1900000000-ce1c08c021fbc1cc5c8c
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-2900000000-94b2b38953d359938c0a
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Phenylpropanes / Aralkylamines / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives
Substituents
Amphetamine or derivatives / Phenylpropane / Aralkylamine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Primary amine / Organonitrogen compound / Primary aliphatic amine / Amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
primary amine (CHEBI:8080)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Stephens LC, Katz SG: Phentermine and anaesthesia. Anaesth Intensive Care. 2005 Aug;33(4):525-7. [PubMed:16119498]
  4. Samanin R, Garattini S: Neurochemical mechanism of action of anorectic drugs. Pharmacol Toxicol. 1993 Aug;73(2):63-8. [PubMed:7902561]
  5. Proietto J, Fam BC, Ainslie DA, Thorburn AW: Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26. [PubMed:11060745]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. John CE, Jones SR: Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices. Neuropharmacology. 2007 Jun;52(8):1596-605. Epub 2007 Mar 16. [PubMed:17459426]
  2. Johnson GJ, Leis LA, Dunlop PC, Weir EK: The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux. J Thromb Haemost. 2003 Dec;1(12):2663-8. [PubMed:14675103]
  3. Mekontso-Dessap A, Brouri F, Pascal O, Lechat P, Hanoun N, Lanfumey L, Seif I, Benhaiem-Sigaux N, Kirsch M, Hamon M, Adnot S, Eddahibi S: Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation. 2006 Jan 3;113(1):81-9. Epub 2005 Dec 27. [PubMed:16380550]
  4. Rothman RB, Ayestas MA, Dersch CM, Baumann MH: Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation. 1999 Aug 24;100(8):869-75. [PubMed:10458725]
  5. Zolkowska D, Rothman RB, Baumann MH: Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther. 2006 Aug;318(2):604-10. Epub 2006 Apr 27. [PubMed:16644904]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. John CE, Jones SR: Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices. Neuropharmacology. 2007 Jun;52(8):1596-605. Epub 2007 Mar 16. [PubMed:17459426]
  2. Gruner JA, Marcy VR, Lin YG, Bozyczko-Coyne D, Marino MJ, Gasior M: The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents. Sleep. 2009 Nov;32(11):1425-38. [PubMed:19928382]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Rothman RB: Is phentermine an inhibitor of monoamine oxidase? A critical appraisal. Synapse. 1999 May;32(2):141-5. [PubMed:10231134]
  2. Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660]
  3. Kilpatrick IC, Traut M, Heal DJ: Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release. Int J Obes Relat Metab Disord. 2001 Oct;25(10):1454-8. [PubMed:11673765]
  4. Nandigama RK, Newton-Vinson P, Edmondson DE: Phentermine inhibition of recombinant human liver monoamine oxidases A and B. Biochem Pharmacol. 2002 Mar 1;63(5):865-9. [PubMed:11911838]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Rothman RB: Does phentermine inhibit monoamine oxidase? Lancet. 1999 Apr 17;353(9161):1362-3. [PubMed:10218558]
  2. Rothman RB: Is phentermine an inhibitor of monoamine oxidase? A critical appraisal. Synapse. 1999 May;32(2):141-5. [PubMed:10231134]
  3. Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660]
  4. Kilpatrick IC, Traut M, Heal DJ: Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release. Int J Obes Relat Metab Disord. 2001 Oct;25(10):1454-8. [PubMed:11673765]
  5. Nandigama RK, Newton-Vinson P, Edmondson DE: Phentermine inhibition of recombinant human liver monoamine oxidases A and B. Biochem Pharmacol. 2002 Mar 1;63(5):865-9. [PubMed:11911838]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Nandigama RK, Newton-Vinson P, Edmondson DE: Phentermine inhibition of recombinant human liver monoamine oxidases A and B. Biochem Pharmacol. 2002 Mar 1;63(5):865-9. [PubMed:11911838]
  2. Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Nandigama RK, Newton-Vinson P, Edmondson DE: Phentermine inhibition of recombinant human liver monoamine oxidases A and B. Biochem Pharmacol. 2002 Mar 1;63(5):865-9. [PubMed:11911838]
  2. Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:34